公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Overall survival with ribociclib plus endocrine therapy in breast cancer | Im S.-A; YEN-SHEN LU ; Bardia A; Harbeck N; Colleoni M; Franke F; Chow L; Sohn J; Lee K.-S; Campos-Gomez S; Villanueva-Vazquez R; Jung K.-H; Chakravartty A; Hughes G; Gounaris I; Rodriguez-Lorenc K; Taran T; Hurvitz S; Tripathy D. | New England Journal of Medicine | 612 | 556 | |
2018 | Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial | Tripathy D; Im S.-A; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz S.A; Chow L; Sohn J; Lee K.S; Campos-Gomez S; Villanueva Vazquez R; Jung K.H; Babu K.G; Wheatley-Price P; De Laurentiis M; Im Y.-H; Kuemmel S; El-Saghir N; Liu M.-C; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; YEN-SHEN LU | The Lancet Oncology | 633 | 545 |